Numerion Labs vs Axtria
Side-by-side comparison of AI visibility scores, market position, and capabilities
Numerion Labs (fka Atomwise) deploys AtomNet deep learning for ultra-fast virtual drug screening; partnered with Sanofi for up to $1.2B in milestones; rebranded Oct 2025 with new APEX platform for hyper-scalable virtual library screening.
About
Numerion Labs, formerly known as Atomwise, is an AI-driven drug discovery company that uses deep learning to accelerate the identification of small molecule drug candidates. The company''s core technology, AtomNet, is a convolutional neural network trained on vast datasets of protein-ligand interactions to predict binding affinity and drug-likeness at scale. In October 2025, Atomwise rebranded as Numerion Labs, reflecting a sharpened strategic focus on ultra-fast virtual screening and the development of its APEX platform for hyper-scalable chemical library screening — a capability validated in partnership with NVIDIA.
Axtria delivers AI-powered analytics and commercial software to 16 of the top 20 global life sciences companies; recognized in two Gartner Hype Cycle reports for 2025, acquired Conexus Solutions in April 2026.
About
Axtria is a global data analytics and software technology company exclusively focused on the life sciences industry, providing AI-powered solutions for commercial operations, advanced analytics, and cloud-based data management for pharmaceutical, biotechnology, and medical device companies. Its integrated platform — Axtria InsightsMAx.ai — combines SalesIQ for field force effectiveness, CustomerIQ for next-best-action engagement, MarketingIQ for commercial investment optimization, and DataMAx for data integration and governance, enabling life sciences companies to coordinate their commercial operations through a unified AI layer.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.